Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PBMWW
Upturn stock ratingUpturn stock rating

Psyence Biomedical Ltd. Warrant (PBMWW)

Upturn stock ratingUpturn stock rating
$0.02
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: PBMWW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -85.19%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.15
52 Weeks Range 0.00 - 0.05
Updated Date 06/28/2025
52 Weeks Range 0.00 - 0.05
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -54.2%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 71171
Shares Outstanding -
Shares Floating 71171
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Psyence Biomedical Ltd. Warrant

stock logo

Company Overview

overview logo History and Background

Psyence Biomedical Ltd. is a life science biotechnology company focused on developing and commercializing naturally-derived psilocybin products for the global mental health crisis. The warrants provide the holder the right to purchase shares of Psyence Biomedical Ltd. stock at a specific price within a specified period.

business area logo Core Business Areas

  • Psychedelic Drug Development: Focuses on the research and development of psilocybin-based therapies for mental health conditions.

leadership logo Leadership and Structure

The information on Psyence Biomedical Ltd.'s leadership team can typically be found on their investor relations website. Organizational structure is likely a standard corporate model for a biotech company.

Top Products and Market Share

overview logo Key Offerings

  • Psilocybin-based Therapies (Development Stage): Psyence Biomedical is focused on developing novel psilocybin therapies, currently in various stages of research and clinical trials. No products are yet commercialized. Competitors include Compass Pathways (CMPS), Atai Life Sciences (ATAI), and Mind Medicine (MNMD).

Market Dynamics

industry overview logo Industry Overview

The psychedelic medicine industry is an emerging market driven by the potential of psychedelic compounds like psilocybin to treat mental health disorders. It is characterized by increasing research, regulatory changes, and growing investor interest.

Positioning

Psyence Biomedical aims to be a leader in the psychedelic medicine space, focusing on developing and commercializing evidence-based psilocybin therapies. It competes with other biotech companies focused on psychedelic drugs.

Total Addressable Market (TAM)

The global market for mental health treatments is substantial, estimated to be billions of dollars annually. The TAM for psychedelic-assisted therapies is still developing, but is expected to reach multiple billions as research matures and regulatory approvals are obtained. Psyence is positioned to capture a portion of this emerging TAM.

Upturn SWOT Analysis

Strengths

  • Focus on psilocybin-based therapies
  • Experienced management team
  • Strategic partnerships

Weaknesses

  • Early stage of development (no commercialized products)
  • High regulatory hurdles
  • Limited financial resources relative to larger competitors

Opportunities

  • Growing acceptance of psychedelic medicine
  • Positive clinical trial results
  • Strategic partnerships and acquisitions

Threats

  • Regulatory setbacks
  • Competition from larger pharmaceutical companies
  • Negative publicity or safety concerns

Competitors and Market Share

competitor logo Key Competitors

  • CMPS
  • ATAI
  • MNMD

Competitive Landscape

Psyence Biomedical operates in a competitive landscape, where success depends on strong science, effective execution, and securing regulatory approval. The first mover advantage is significant.

Growth Trajectory and Initiatives

Historical Growth: Growth is based on the progress of their drug development pipeline.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of their psilocybin therapies.

Recent Initiatives: Recent initiatives would likely involve clinical trial advancements, partnerships, and financing activities.

Summary

Psyence Biomedical is an early-stage biotech company in the emerging psychedelic medicine field. Its success hinges on the development and regulatory approval of its psilocybin-based therapies. It faces competition from larger, well-funded companies and regulatory hurdles, requiring strategic execution and capital management to achieve long-term growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • Financial news sources
  • Industry reports

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investors should conduct their own due diligence before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Psyence Biomedical Ltd. Warrant

Exchange NASDAQ
Headquaters Toronto, ON, Canada
IPO Launch date 2024-01-26
CEO & Director Dr. Neil Maresky M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 12
Full time employees 12

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.